Back to News
Market Impact: 0.3
Pharming Group Q3 Earnings Call Highlights
Source: marketbeat.com
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Pharming Group reported third-quarter revenue growth of 21% to $117.6 million. The company attributed the increase to higher sales of RUCONEST, its hereditary angioedema treatment, and Joenja for APDS.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
PHAR0.55
More News
- Pharming Q3 operating profit jumps 89%, narrows 2026 revenue outlook
- SK Hynix third-quarter profit sharply beats estimates on AI memory boost
- SK Hynix Posts Record Profit Amid AI Rush
- Anthropic's IPO could be 'speculative fiction' or a 'generational moment' — investors are split
- Anthropic Gives Traders a Pure-Play Bet on Frontier AI
- VCs will make billions on Anthropic’s IPO, but Amazon is set to make much (much) more